Briefing
Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
Adults with acute lymphoblastic leukemia who underwent allogeneic transplant were evaluated for measurable residual disease with the clonoSEQ assay before and after transplant.
- Design: Evidence level 3
- Assay: clonoSEQ
Blood AdvancesPubMed 37196642DOI 10.1182/bloodadvances.2023009856